What translatable knowledge from dengue vaccine design can we pass onto future anti-parasitic vaccine development?

References

• Pierson TC, Diamond MS, Flavivirus, Fields virology. Knipe DM,Howly P, 6th ed. Philadelphia (PA), Lippincott Williams & Wilkins. 2013.
   Google Scholar
• Nimmannitya S. Clinical manifestations of dengue/dengue haemorrhagic fever. In: Thongcharoen P, editor. Monograph on dengue/dengue haemorrhagic fever. New Delhi: World Health Organization; 1993. p. 48–57.
   Google Scholar
• Burke DS, Nisalak A, Johnson DE, et al. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988;38(1):172–180.
   PubMed Web of Science ®Google Scholar
• Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol. 1984;120(5):653–669.
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Mathew A, Rothman AL. Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol. 2017;39(5):563–574.
   PubMed Web of Science ®Google Scholar
• Mongkolsapaya J, Duangchinda T, Dejnirattisai W, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol. 2006;176(6):3821–3829.
   PubMed Web of Science ®Google Scholar
• Mangada MM, Endy TP, Nisalak A, et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis. 2002;185(12):1697–1703.
   PubMed Web of Science ®Google Scholar
• Zellweger RM, Tang WW, Eddy WE, et al. CD8+ T cells can mediate short-term protection against heterotypic dengue virus reinfection in Mice. J Virol. 2015;89(12):6494–6505.
   PubMed Web of Science ®Google Scholar
• Gil L, Cobas K, Lazo L, et al. A tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces a functional immune response in mice and monkeys. J Immunol. 2016;197(9):3597–3606.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, Grifoni A, et al. HLA-DRB1 alleles are associated with different magnitudes of dengue virus-specific CD4+ T-cell responses. J Infect Dis. 2016;214(7):1117–1124.
   PubMed Web of Science ®Google Scholar
• Elong Ngono A, Chen HW, Tang WW, et al. Protective role of cross-reactive CD8 T cells against dengue virus infection. EBioMedicine. 2016;13:284–293.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–1365.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the sanofi-pasteur CYD vaccine? Expert Rev Vaccines. 2016;15(4):509–517.
   PubMed Web of Science ®Google Scholar
• Biswal S, Reynales H, Saez-Llorens X, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;381(21):2009–2019.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Tricou V, Yu D, et al. Safety and immunogenicity of one versus two doses of takeda’s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis. 2017;17(6):615–625.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170–177.
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Yoon IK. Immune correlates for dengue vaccine development. Expert Rev Vaccines. 2016;15(4):455–465.
   PubMed Web of Science ®Google Scholar
• Weiskopf D, Angelo MA, de Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A. 2013;110(22):E2046–2053.
   PubMed Web of Science ®Google Scholar
• Beatty PR, Puerta-Guardo H, Killingbeck SS, et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med. 2015;7(304):304ra141.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328(5979):745–748.
   PubMed Web of Science ®Google Scholar
• Tran NH, Chansinghakul D, Chong CY, et al. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. Hum Vaccin Immunother. 2019;15(10):2315–2327.
   Web of Science ®Google Scholar
• Borges MB, Marchevsky RS, Carvalho Pereira R, et al. Detection of post-vaccination enhanced dengue virus infection in macaques: an improved model for early assessment of dengue vaccines. PLoS Pathog. 2019;15(4):e1007721.
   PubMed Web of Science ®Google Scholar
• Kurup SP, Butler NS, Harty JT. T cell-mediated immunity to malaria. Nat Rev Immunol. 2019;19(7):457–471.
   PubMed Web of Science ®Google Scholar
• Novais FO, Scott P. CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly. Semin Immunopathol. 2015;37(3):251–259.
   PubMed Web of Science ®Google Scholar
• Henein S, Swanstrom J, Byers AM, et al. Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals. J Infect Dis. 2017;215(3):351–358.
   PubMed Web of Science ®Google Scholar
• Julien JP, Wardemann H. Antibodies against plasmodium falciparum malaria at the molecular level. Nat Rev Immunol. 2019;19:761–775.
   PubMed Web of Science ®Google Scholar
• Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011;11(2):102–109.
   PubMed Web of Science ®Google Scholar
• Moris P, Jongert E, van der Most RG. Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine. Hum Vaccin Immunother. 2018;14(1):17–27.
   PubMed Web of Science ®Google Scholar
• Chaudhury S, Ockenhouse CF, Regules JA, et al. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity. Malar J. 2016;15:301.
   PubMed Web of Science ®Google Scholar
• Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol. 2016;16(9):581–592.
   PubMed Web of Science ®Google Scholar
• Cecílio P, Oliveira F, Silva A. Vaccines for human leishmaniasis: where do we stand and what is still missing? In: Afrin F, Hemeg H, editors. Leishmaniases as re-emerging diseases. IntechOpen; 2018. [Last accessed 2019 Nov 8]. Available from: https://www.intechopen.com/books/leishmaniases-as-re-emerging-diseases/vaccines-for-human-leishmaniasis-where-do-we-stand-and-what-is-still-missing
   Google Scholar
• Sun P, Schwenk R, White K, et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol. 2003;171(12):6961–6967.
   PubMed Web of Science ®Google Scholar
• Barbosa A, Naniche D, Aponte JJ, et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect Immun. 2009;77(10):4502–4509.
   PubMed Web of Science ®Google Scholar
• Osman M, Mistry A, Keding A, et al. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH. PLoS Negl Trop Dis. 2017;11(5):e0005527.
   PubMed Web of Science ®Google Scholar
• Malaria vaccine launched in Kenya: kenya joins Ghana and Malawi to roll out landmark vaccine in pilot introduction. Malaria Vaccine Implementation Programme, World Health Organization; 2019 [cited 2020 Jan 8]. Available from: https://www.afro.who.int/news/malaria-vaccine-launched-kenya-kenya-joins-ghana-and-malawi-roll-out-landmark-vaccine-pilot
   Google Scholar